Literature DB >> 5229352

[Trial of treatment of acute lymphoblastic and myeloblastic leukemias by a new antibiotic: rubidomycin (RP 13,057). Study of 61 cases].

J Bernard, C Jacquillat, M Boiron, Y Najean, M Seligmann, J Tanzer, M Weil, P Lortholary.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1967        PMID: 5229352

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0032-7867            Impact factor:   1.228


× No keyword cloud information.
  9 in total

Review 1.  What Is the Best Daunorubicin Dose and Schedule for Acute Myeloid Leukemia Induction?

Authors:  Priyanka Pophali; Mark Litzow
Journal:  Curr Treat Options Oncol       Date:  2017-01

2.  Daunorubicin. Results in childhood leukaemia.

Authors:  R N Matthews; J H Colebatch
Journal:  Arch Dis Child       Date:  1972-04       Impact factor: 3.791

3.  Daunorubicin in acute leukaemia.

Authors:  R L Souhami; T A Prankerd
Journal:  Postgrad Med J       Date:  1970-05       Impact factor: 2.401

4.  Acute leukaemia--the current therapeutic position.

Authors:  R B Scott
Journal:  Proc R Soc Med       Date:  1968-05

5.  Evidence for non-infiltrative cardiomyopathy in acute leukaemia and lymphoma. A clinical and echocardiographic study.

Authors:  M A Mir
Journal:  Br Heart J       Date:  1978-07

6.  Mode of action of chemotherapy in vivo on human acute leukemia. I. Daunomycin.

Authors:  P A Stryckmans; J Manaster; F Lachapelle; M Socquet
Journal:  J Clin Invest       Date:  1973-01       Impact factor: 14.808

7.  The treatment of acute myeliod leukaemia.

Authors:  J H Friend; C Giles; S G Richardson
Journal:  J Clin Pathol       Date:  1974-01       Impact factor: 3.411

8.  Rubidomycin in acute leukaemia in adults.

Authors:  J S Malpas; R B Scott
Journal:  Br Med J       Date:  1968-07-27

9.  Daunorubicin metabolism: estimation of daunorubicin reductase.

Authors:  N R Bachur; D H Huffman
Journal:  Br J Pharmacol       Date:  1971-12       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.